A single defective purchased component can pull finished kits across multiple assemblers at once. The FDA classified a Class I recall of Medline's Namic Angiographic Rotating Adaptor Control Syringes after post-market surveillance found the rotating adaptor could unwind, causing loose connections or disconnections with risks of biohazard exposure, blood loss, infection, or air embolism (FDA Medical Device Recall Notice: Medline Namic Angiographic Rotating Adaptor Control Syringes).
Because that syringe shipped into convenience kits as a purchased component, the recall did not stop at the syringe. Several separate contract kit assemblers issued parallel recalls of kits containing it. That is the part of the story the recall notices do not analyze, and the part that matters most if you build or buy convenience kits.
What the public record shows
The Medline action covered 966 convenience kits containing the Namic syringes, distributed nationally and internationally, and was classified Class I, the most serious recall type (Becker's Hospital Review: FDA recalls Medline kits tied to syringe defect). As of March 13, Medline had reported four serious injuries and no deaths associated with the defect.
The downstream recalls followed the same component. American Contract Systems removed Coronary Angio Pack convenience kits containing the recalled syringes, classified as the most serious recall type (FDA Medical Device Recall Record: American Contract Systems Convenience Kit Recall). AVID Medical issued an Urgent Medical Device Recall, instructing customers to identify, over-label, and remove affected syringes (FDA Medical Device Recall Record: AVID Medical Convenience Kit Recall). Medical Action Industries removed Cath Pack convenience kits containing the affected syringes, with all units potentially able to exhibit the failure mode (FDA Medical Device Recall Record: Medical Action Industries Convenience Kit Recall).
The FDA notices and the trade coverage frame this as a component defect and a field-remediation exercise: find the syringes, over-label, quarantine, destroy. That framing is correct as far as it goes. But it leaves an open question for anyone running a kitting line. The defect originated in a purchased component. What governs how a kit assembler accepts, controls, and verifies the components it buys before they reach a finished kit?
A scope note before we go further
The Namic failure mode is mechanical and component-specific: a rotating adaptor that can unwind. It would be wrong to generalize that mechanism to convenience-kit defects broadly, and we are not doing that here. The unwinding adaptor was Medline's design and manufacturing issue, not an assembly-line error introduced by the kitters.
What the incident does illustrate is structural: when several assemblers buy the same component, a single defect creates correlated exposure across all of them at once. The lesson isn't "the assemblers built the syringe wrong." It's that the controls governing purchased components and finished-kit acceptance are the assembler's first and last line of defense, and they operate whether or not the OEM catches a defect upstream.
Where the QMS controls actually live
Under the QMSR, the FDA quality-system framework now incorporates ISO 13485:2016 by reference. The clauses that govern convenience-kit assembly are specific, and they map directly onto the exposure this recall illustrates.
Purchasing and supplier control. ISO 13485 requires organizations to establish documented purchasing controls and to evaluate and select suppliers based on their ability to supply product meeting requirements, with verification of purchased product proportionate to risk (ISO 13485:2016 Clause 7.4). For a kit assembler, the Namic syringe is purchased product. Clause 7.4 places responsibility on the assembler to control it: supplier qualification, defined acceptance criteria, and verification scaled to the component's risk.
Incoming and finished-kit acceptance. ISO 13485 requires receiving, in-process, and final acceptance activities to verify that purchased components and finished product meet specified requirements before release, with records identifying the person authorizing release (ISO 13485:2016 Clause 8.2.6). This is the basis for incoming-inspection sampling on purchased components and for post-assembly inspection sampling on completed kits. A defect that is detectable at incoming or final acceptance should not reach distribution; the acceptance plan is what makes that determination explicit and recorded.
Controlled production. ISO 13485 requires manufacturers to plan and carry out production under controlled conditions, including documented procedures, work instructions, monitoring of process parameters, and process validation where output cannot be verified by subsequent monitoring (ISO 13485:2016 Clause 7.5). This is where line setup qualification and work-instruction discipline live. The control matters because it determines whether the right component, in the right configuration, with the right inspection step, is built into every kit consistently.
Work environment. ISO 13485 Clause 6.4 requires manufacturers to define and control work-environment and contamination requirements based on product risk, referencing ISO 14644 and ISO 14698 for cleanroom and contamination control (ISO 13485:2016 Clause 6.4). Clause 6.4 governs the environment, not the mechanical-assembly discipline most relevant to a defect like the unwinding adaptor, worth naming so the controls aren't conflated. Environmental control keeps contamination out; acceptance and production control keep nonconforming product out.
Reactive containment vs. designed-in prevention
The downstream recall instructions tell you where the burden falls when a component defect surfaces after distribution. Identify affected lots. Over-label. Quarantine. Remove and destroy. That is field-corrective remediation: necessary, costly, and reactive.
The controls described above are the other side of that ledger. Clause 7.4 supplier verification and Clause 8.2.6 acceptance sampling are the steps that determine whether a nonconforming component is caught before it is built into a kit or shipped. When a defect is detectable at incoming or final inspection, the acceptance plan is what stands between the component and the patient.
We want to be careful about what these controls can and cannot do. No acceptance sampling plan catches a latent mechanical defect that only manifests in use and produces no detectable signal at inspection. The Namic adaptor-unwind mode may or may not have been screenable at incoming inspection. The public record doesn't say, and we won't speculate. The point is narrower and defensible: the QMS clauses that govern purchased-component control and finished-kit release are where a kit assembler's prevention capability is concentrated, and they are auditable, documented, and risk-proportionate by design.
The OEM's responsibility doesn't transfer
There's a related lesson for OEMs that outsource kitting. FDA supplier-control enforcement consistently reinforces that OEMs retain full responsibility for supplier and contractor quality lapses; outsourcing the build does not outsource the responsibility.
For an OEM evaluating a kitting partner, that makes the partner's Clause 7.4 and Clause 8.2.6 documentation a direct part of your own quality file. Supplier qualification records, defined acceptance criteria, sampling plans, and release authorization records are the artifacts an auditor will trace when a component issue surfaces. If those controls are thin at your assembler, they are thin in your submission.
What to ask a kitting partner
The Namic recall is a useful lens for a supplier-qualification conversation. Concrete questions worth asking any convenience-kit assembler:
- How are component suppliers qualified, and how is purchased-product verification scaled to component risk (Clause 7.4)?
- What incoming-acceptance and post-assembly inspection sampling plans apply, and who authorizes release (Clause 8.2.6)?
- How are work instructions controlled and line setup qualified before a build runs (Clause 7.5)?
- How are quality holds propagated between kitting and assembly so a held lot can't be built into a finished kit?
Those questions don't depend on the specific failure mode. They get at whether the assembler's QMS is designed to keep nonconforming components out of finished kits in the first place, which is the durable lesson when one defective purchased part can pull kits across multiple assemblers at once.